This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Aram Mangasarian, Ph.D.
Chief Executive Officer at NOXXON Pharma AG


Aram Mangasarian is the CEO of NOXXON Pharma – a lean, publicly quoted company focused on targeting the tumor microenvironment to improve the treatment of solid tumors. Aram brings over twenty years experience in the biotechnology industry to NOXXON. 

Prior to joining NOXXON, initially as CBO, Aram served as VP Business Development for Novexel where he concluded a €150 million licensing agreement including a €75 million upfront payment with Forest Laboratories for North American rights to a Phase I beta-lactamase inhibitor now commercialized as avibactam. Aram was a member of the leadership team that negotiated the acquisition of Novexel by AstraZeneca for up to $505 million. 

Prior to Novexel, Aram served in a variety of roles at ExonHit Therapeutics, eventually heading the business development function as Vice-President. He concluded a number of important agreements for ExonHit, in particular the $30 million strategic alliance with Allergan.

Aram is a non-executive member of the board of directors of Isofol Medical AB, based in Gothenburg, Sweden, since June 2020.

Aram received a B.S. from the University of Wisconsin-Madison in biochemistry, molecular biology and English literature, a PhD in Biology from the University of California-San Diego for research carried out on the molecular biology of HIV at the Salk Institute and an MBA from INSEAD.

Agenda Sessions

  • Enhancing Efficacy and Safety in Rare Solid Tumor Therapies with Oligonucleotide Tumor Microenvironment Modulators